Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06121349 · ClinicalTrials.gov registry record
WOE of Anti-CD20 Therapies
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 157
- Enrollment target
NCT06121349 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 157 participants.
The verdict
NCT06121349 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 157 participants
- Enrollment target
Study Summary
The nature, intensity, and prevalence of this wearing-off effect remain poorly understood. To our knowledge, there is no consensus in the literature on what symptoms constitute a wearing-off effect, nor is there a single validated scale that measures wearing-off effect. The current study will explore the wearing-off effect associated with OCR and OMB, using a variety of validated scales assessing MS symptoms (i.e., fatigue, mobility, pain, depression, cognition), as well as some global questions on wearing-off. In addition, impact of worsening of MS symptoms on patients' health-related quality of life (HRQoL) and their work productivity will be assessed using relevant MS-specific validated scales
Interventions
- DRUG ofatumumab
- DRUG ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2025-06-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06121349
The ClinicalTrials.gov registry entry for NCT06121349 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ofatumumab is the first listed.
NCT06121349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06121349 about?
NCT06121349 is a clinical study titled "WOE of Anti-CD20 Therapies". The nature, intensity, and prevalence of this wearing-off effect remain poorly understood. To our knowledge, there is no consensus in the literature on what symptoms constitute a wearing-off effect, nor is there a single validated scale that measures wearing-off effect. The current study will explor...
What is the current status of trial NCT06121349?
This trial is currently completed. The enrollment target is 157 participants. The study started on 2023-12-04. Estimated completion is 2025-06-13.
What interventions are being tested in trial NCT06121349?
The interventions under investigation include: ofatumumab (DRUG), ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT06121349?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.